Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.
作者信息
Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Habiyaremye I
出版信息
Antimicrob Agents Chemother. 1986 May;29(5):883-6. doi: 10.1128/AAC.29.5.883.
Abstract
A severe epidemic of dysentery began late in 1979 in northeast Zaire and spread to Rwanda, Burundi, and Tanzania. The epidemic strain is a multiply resistant Shigella dysenteriae type 1, which acquired resistance against trimethoprim and more recently against nalidixic acid in the course of the epidemic. A comparative open trial in Rwandan adults with Shiga dysentery involved 18 patients treated with norfloxacin at 400 mg twice daily and 12 patients treated with nalidixic acid at 1 g three times daily for 5 days. All isolates showed in vitro susceptibility to both drugs. Though norfloxacin eliminated Shigella organisms from stools more rapidly than nalidixic acid, its clinical superiority did not reach the level of significance. Norfloxacin is a promising drug and is more effective than nalidixic acid in the treatment of multiresistant shigellosis.
摘要
相似文献
1
Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.
Antimicrob Agents Chemother. 1986 May;29(5):883-6. doi: 10.1128/AAC.29.5.883.
2
Efficacy of norfloxacin for shigellosis: a double-blind randomised clinical trial.
J Diarrhoeal Dis Res. 1992 Sep;10(3):146-50.
3
Randomized clinical trial of norfloxacin for shigellosis.
Am J Trop Med Hyg. 1991 Dec;45(6):683-7. doi: 10.4269/ajtmh.1991.45.683.
4
Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.
J Antimicrob Chemother. 1987 May;19(5):695-8. doi: 10.1093/jac/19.5.695.
5
Outbreak of dysentery due to nalidixic acid resistant S. dysenteriae 1 at Agartala, Tripura: a hospital based study.
Indian J Public Health. 1990 Jan-Mar;34(1):11-4.
6
Epidemic Shiga bacillus dysentery in Central Africa.
Am J Trop Med Hyg. 1984 Nov;33(6):1192-7. doi: 10.4269/ajtmh.1984.33.1192.
7
Epidemic dysentery caused by Shigella dysenteriae type 1: a sentinel site surveillance of antimicrobial resistance patterns in Burundi.
Bull World Health Organ. 1995;73(6):787-91.
8
Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance.
Diagn Microbiol Infect Dis. 1997 Aug;28(4):165-71. doi: 10.1016/s0732-8893(97)00072-2.
9
Plasmid characterization of drug-resistant Shigella dysenteriae 1 from an epidemic in Central Africa.
J Hyg (Lond). 1985 Apr;94(2):163-72. doi: 10.1017/s0022172400061362.
10
[An outbreak of Shigella dysenteriae type 1 dysentery in a refugee camp in Rwanda].
Sante. 1995 May-Jun;5(3):181-4.
引用本文的文献
1
Transferable Mechanisms of Quinolone Resistance from 1998 Onward.
Clin Microbiol Rev. 2019 Aug 14;32(4). doi: 10.1128/CMR.00007-19. Print 2019 Sep 18.
2
Efficacy and potential of phage therapy against multidrug resistant spp.
PeerJ. 2019 Apr 5;7:e6225. doi: 10.7717/peerj.6225. eCollection 2019.
3
Antibiotic therapy for Shigella dysentery.
Cochrane Database Syst Rev. 2010 Aug 4;2010(8):CD006784. doi: 10.1002/14651858.CD006784.pub4.
4
A look back at an ongoing problem: Shigella dysenteriae type 1 epidemics in refugee settings in Central Africa (1993-1995).
PLoS One. 2009;4(2):e4494. doi: 10.1371/journal.pone.0004494. Epub 2009 Feb 13.
5
Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources.
BMC Public Health. 2007 Jan 19;7:8. doi: 10.1186/1471-2458-7-8.
6
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.
Antimicrob Agents Chemother. 2001 Jan;45(1):212-6. doi: 10.1128/AAC.45.1.212-216.2001.
7
The new quinolones in the treatment of diarrhoea and typhoid fever.
Drugs. 1995;49 Suppl 2:132-5. doi: 10.2165/00003495-199500492-00021.
8
Acute bacterial diarrhoea in the emergency room: therapeutic implications of stool culture results.
J Accid Emerg Med. 1994 Sep;11(3):168-71. doi: 10.1136/emj.11.3.168.
9
Quinolones in the treatment of acute bacterial diarrhoeal diseases.
Drugs. 1993;45 Suppl 3:114-8. doi: 10.2165/00003495-199300453-00019.
10
Problems in identification of Campylobacter jejuni associated with acquisition of resistance to nalidixic acid.
J Clin Microbiol. 1987 Sep;25(9):1807-8. doi: 10.1128/jcm.25.9.1807-1808.1987.
本文引用的文献
1
Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis.
Scand J Infect Dis. 1981;13(3):191-3. doi: 10.3109/inf.1981.13.issue-3.06.
2
Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.
Antimicrob Agents Chemother. 1983 Oct;24(4):509-13. doi: 10.1128/AAC.24.4.509.
3
A bacillary dysentery epidemic in Dar es Salaam, Tanzania.
J Diarrhoeal Dis Res. 1984 Dec;2(4):217-22.
4
Drug resistance in Shigella dysenteriae, S flexneri and S boydii in England and Wales: increasing incidence of resistance to trimethoprim.
Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):784-6. doi: 10.1136/bmj.288.6419.784.
5
Epidemic Shiga bacillus dysentery in Central Africa.
Am J Trop Med Hyg. 1984 Nov;33(6):1192-7. doi: 10.4269/ajtmh.1984.33.1192.
6
Outbreak of Shigella dysentery in Eastern Zaire, 1980-1982.
Ann Soc Belg Med Trop. 1983 Mar;63(1):59-67.
7
The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.
J Antimicrob Chemother. 1983 Apr;11(4):369-76. doi: 10.1093/jac/11.4.369.
8
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
Antimicrob Agents Chemother. 1983 Jan;23(1):86-90. doi: 10.1128/AAC.23.1.86.
9
Epidemic of dysentery in West Bengal: clinicians' enigma.
Lancet. 1984 Nov 17;2(8412):1160. doi: 10.1016/s0140-6736(84)91600-3.
10
Nalidixic acid analogues and Shigella.
Lancet. 1984 Jul 21;2(8395):172-3. doi: 10.1016/s0140-6736(84)91094-8.
Zotero 插件